Loperamide Versus Psyllium Fiber for Treatment of Fecal Incontinence: The Fecal Incontinence Prescription (Rx) Management (FIRM) Randomized Clinical Trial

Diseases of the Colon and Rectum

Volumn 58, Issue 10, 2015, Pages 983-993

  Markland, Alayne D ^a,b   Burgio, Kathryn L ^a,b   Whitehead, William E ^c   Richter, Holly E ^d   Wilcox, C Mel ^e   Redden, David T ^f   Beasley, Timothy M ^f   Goode, Patricia S ^a,b  

^a BIRMINGHAM VA MEDICAL CENTER   (United States)

^b University of Alabama at Birmingham   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e University of Alabama at Birmingham   (United States)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Accidental bowel leakage; Comparative effectiveness; Crossover design; Fecal incontinence; Functional bowel disorders; Quality of life; Randomized controlled trial

Indexed keywords

ISPAGULA; LOPERAMIDE; PLACEBO; ANTIDIARRHEAL AGENT; LAXATIVE;

ABDOMINAL PAIN; ADULT; ARTICLE; BLOATING; CONSTIPATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG EFFICACY; DRUG TOLERABILITY; FECES INCONTINENCE; FEMALE; FLATULENCE; HEADACHE; HEARTBURN; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; NAUSEA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RASH; RECTUM HEMORRHAGE; SORE THROAT; SYMPTOMATOLOGY; AGED; DRUG ADMINISTRATION; FECAL INCONTINENCE; PATHOPHYSIOLOGY; PSYCHOLOGY; SYMPTOM ASSESSMENT; TREATMENT OUTCOME;

AGED; ANTIDIARRHEALS; CATHARTICS; CONSTIPATION; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FECAL INCONTINENCE; FEMALE; HUMANS; LOPERAMIDE; MALE; MIDDLE AGED; PSYLLIUM; QUALITY OF LIFE; SYMPTOM ASSESSMENT; TREATMENT OUTCOME;

EID: 84941917139     PISSN: 00123706     EISSN: 15300358     Source Type: Journal    
DOI: 10.1097/DCR.0000000000000442     Document Type: Article

References (36)

1. Bartlett L, Nowak M, Ho YH. Impact of fecal incontinence on quality of life. World J Gastroenterol. 2009;15:3276-3282.
2. Whitehead WE, Borrud L, Goode PS, et al. Fecal incontinence in US adults: epidemiology and risk factors. Gastroenterology. 2009;137:512-517.
3. Markland AD, Goode PS, Burgio KL, et al. Incidence and risk factors for fecal incontinence in black and white older adults: a population-based study. J Am Geriatr Soc. 2010;58:1341-1346.
4. Bharucha AE, Zinsmeister AR, Locke GR, et al. Prevalence and burden of fecal incontinence: a population-based study in women. Gastroenterology. 2005;129:42-49.
5. Chiang L, Ouslander J, Schnelle J, Reuben DB. Dually incontinent nursing home residents: clinical characteristics and treatment differences. J Am Geriatr Soc. 2000;48:673-676.
6. Quander CR, Morris MC, Melson J, Bienias JL, Evans DA. Prevalence of and factors associated with fecal incontinence in a large community study of older individuals. Am J Gastroenterol. 2005;100:905-909.
7. Dunivan GC, Heymen S, Palsson OS, et al. Fecal incontinence in primary care: prevalence, diagnosis, and health care utilization. Am J Obstet Gynecol. 2010;202:493. e1-493. e6.
8. Ditah I, Devaki P, Luma HN, et al. Prevalence, trends, and risk factors for fecal incontinence in United States adults, 2005-2010. Clin Gastroenterol Hepatol. 2014;12:636-43. e1.
9. Matthews CA, Whitehead WE, Townsend MK, Grodstein F. Risk factors for urinary, fecal, or dual incontinence in the Nurses' Health Study. Obstet Gynecol. 2013;122:539-545.
10. Burgell RE, Bhan C, Lunniss PJ, Scott SM. Fecal incontinence in men: coexistent constipation and impact of rectal hyposensitivity. Dis Colon Rectum. 2012;55:18-25.
11. Qureshi MS, Rao MM, Sasapu KK, et al. Male faecal incontinence presents as two separate entities with implications for management. Int J Colorectal Dis. 2011;26:1589-1594.
12. H arari D, Husk J, Lowe D, Wagg A. National audit of continence care: adherence to National Institute for Health and Clinical Excellence (NICE) guidance in older versus younger adults with faecal incontinence. Age Ageing. 2014;43:785-793.
13. Norton C, Thomas L, Hill J; Guideline Development Group. Management of faecal incontinence in adults: summary of NICE guidance. BMJ. 2007;334:1370-1371.
14. Luppa M, Luck T, Brähler E, König HH, Riedel-Heller SG. Prediction of institutionalisation in dementia: a systematic review. Dement Geriatr Cogn Disord. 2008;26:65-78.
15. T homas P, Ingrand P, Lalloue F, et al. Reasons of informal caregivers for institutionalizing dementia patients previously living at home: the Pixel study. Int J Geriatr Psychiatry. 2004;19:127-135.
16. Wald A, Bharucha AE, Cosman BC, Whitehead WE. ACG clinical guideline: management of benign anorectal disorders. Am J Gastroenterol. 2014;109:1141-1157.
17. Bharucha AE, Rao SS. An update on anorectal disorders for gastroenterologists. Gastroenterology. 2014;146:37-45. e2.
18. Norton C, Cody JD. Biofeedback and/or sphincter exercises for the treatment of faecal incontinence in adults. Cochrane Database Syst Rev. 2012;(7):CD002111.
19. Maeda Y, Laurberg S, Norton C. Perianal injectable bulking agents as treatment for faecal incontinence in adults. Cochrane Database Syst Rev. 2010;(5):CD007959.
20. O mar MI, Alexander CE. Drug treatment for faecal incontinence in adults. Cochrane Database Syst Rev. 2013;(6):CD002116.
21. Brown SR, Wadhawan H, Nelson RL. Surgery for faecal incontinence in adults. Cochrane Database Syst Rev. 2013;(7):CD001757.
22. Maeda Y, Laurberg S, Norton C. Perianal injectable bulking agents as treatment for faecal incontinence in adults. Cochrane Database Syst Rev. 2013;(2):CD007959.
23. Bliss DZ, Savik K, Jung HJ, Whitebird R, Lowry A, Sheng X. Dietary fiber supplementation for fecal incontinence: a randomized clinical trial. Res Nurs Health. 2014;37:367-378.
24. Read M, Read NW, Barber DC, Duthie HL. Effects of loperamide on anal sphincter function in patients complaining of chronic diarrhea with fecal incontinence and urgency. Dig Dis Sci. 1982;27:807-814.
25. Heaton KW, Radvan J, Cripps H, Mountford RA, Braddon FE, Hughes AO. Defecation frequency and timing, and stool form in the general population: a prospective study. Gut. 1992;33:818-824.
26. Camilleri M, Rothman M, Ho KF, Etropolski M. Validation of a bowel function diary for assessing opioid-induced constipation. Am J Gastroenterol. 2011;106:497-506.
27. Rockwood TH, Church JM, Fleshman JW, et al. Patient and surgeon ranking of the severity of symptoms associated with fecal incontinence: the Fecal Incontinence Severity Index. Dis Colon Rectum. 1999;42:1525-1532.
28. Kwon S, Visco AG, Fitzgerald MP, Ye W, Whitehead WE. Validity and reliability of the Modified Manchester Health Questionnaire in assessing patients with fecal incontinence. Dis Colon Rectum. 2005;48:323-331.
29. Jelovsek JE, Chen Z, Markland AD, et al. Minimum important differences for scales assessing symptom severity and quality of life in patients with fecal incontinence. Female Pelvic Med Reconstr Surg. 2014;20:342-348.
30. Burgio KL, Goode PS, Richter HE, Locher JL, Roth DL. Global ratings of patient satisfaction and perceptions of improvement with treatment for urinary incontinence: validation of three global patient ratings. Neurourol Urodyn. 2006;25:411-417.
31. Diggle P. Analysis of Longitudinal Data. 2nd ed. Oxford, United Kingdom: Oxford University Press; 2013.
32. S enn SJ, Hildebrand H. Crossover trials, degrees of freedom, the carryover problem and its dual. Stat Med. 1991;10:1361-1374.
33. L auti M, Scott D, Thompson-Fawcett MW. Fibre supplementation in addition to loperamide for faecal incontinence in adults: a randomized trial. Colorectal Dis. 2008;10:553-562.
34. Heymen S, Scarlett Y, Jones K, Ringel Y, Drossman D, Whitehead WE. Randomized controlled trial shows biofeedback to be superior to pelvic floor exercises for fecal incontinence. Dis Colon Rectum. 2009;52:1730-1737.
35. Mills EJ, Chan AW, Wu P, Vail A, Guyatt GH, Altman DG. Design, analysis, and presentation of crossover trials. Trials. 2009;10:27.
36. Cummings P. Carryover bias in crossover trials. Arch Pediatr Adolesc Med. 2010;164:703-705.